Campath and Arrhythmias - a phase IV clinical study of FDA data

Summary:

Arrhythmias is reported as a side effect among people who take Campath (alemtuzumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Fludarabine Phosphate, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Arrhythmias when taking Campath. It is created by eHealthMe based on reports of 4,897 people who have side effects when taking Campath from the FDA, and is updated regularly.

What is Campath?

Campath has active ingredients of alemtuzumab. eHealthMe is studying from 4,909 Campath users. Check the latest studies of Campath.

What is Arrhythmias?

Arrhythmias (irregular heartbeat) is found to be associated with 2,759 drugs and 4,837 conditions by eHealthMe. Check the latest studies of Arrhythmias.

On Jul, 11, 2026

4,897 people reported to have side effects when taking Campath.
Among them, 72 people (1.47%) have Arrhythmias.

Among these 72 people:

How long have people been on Campath when they have Arrhythmias? *

What is the gender of people who have Arrhythmias when taking Campath? *

female: 44.93 %
male: 55.07 %

What is the age of people who have Arrhythmias when taking Campath? *

What are other drugs people take besides Campath? *

Fludarabine Phosphate: 15 people, 20.83%
Bactrim: 13 people, 18.06%
Solu-Medrol: 10 people, 13.89%
Cyclophosphamide: 9 people, 12.50%
Paracetamol: 8 people, 11.11%
Allopurinol: 8 people, 11.11%
Fludara: 7 people, 9.72%
Acetaminophen: 5 people, 6.94%
Cyclosporine: 5 people, 6.94%
Prednisone: 5 people, 6.94%

What are other side effects people have besides Arrhythmias? *

Fever: 33 people, 45.83%
Hypotension (abnormally low blood pressure): 29 people, 40.28%
Dyspnea (difficult or laboured breathing): 19 people, 26.39%
Pleural Effusion (water on the lungs): 18 people, 25.00%
Nausea (feeling of having an urge to vomit): 17 people, 23.61%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 16 people, 22.22%
Septic Shock (shock due to blood infection): 15 people, 20.83%
Abdominal Pain: 15 people, 20.83%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 15 people, 20.83%
Rashes (redness): 15 people, 20.83%

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 25 people, 34.72%
Bone Marrow Conditioning Regimen: 5 people, 6.94%
Histiocytosis Haematophagic: 4 people, 5.56%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 4 people, 5.56%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 3 people, 4.17%
T-Cell Prolymphocytic Leukaemia (a aggressive type of t cell cancer): 3 people, 4.17%
Constipation: 2 people, 2.78%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 2 people, 2.78%
High Blood Cholesterol: 2 people, 2.78%
Non-Hodgkin's Lymphoma Recurrent (reoccurrence malignant (cancer) cells form in the lymph system): 2 people, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Campath and have Arrhythmias?

- Check whether Arrhythmias is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Campath:

Campath (4,909 reports)

Arrhythmias treatments and more:

Arrhythmias (177,908 reports)

Browse all side effects of Campath:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Arrhythmias:

Arrhythmias (2,759 drugs)

Browse all the conditions that are associated with Arrhythmias:

Arrhythmias (4,837 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on alemtuzumab (the active ingredients of Campath) and Campath (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.